Creative Biolabs expands anti-glycopeptide antibody discovery workflow

Creative Biolabs has launched an optimized anti-glycopeptide antibody development workflow aimed at speeding cancer therapeutic programs that depend on hard-to-discover glycopeptide targets. The platform is designed to improve specificity and reduce technical barriers tied to weak immunogenicity, cross-reactivity and antigen instability.

Why it matters: - Glycopeptide neoepitopes are emerging as valuable cancer targets because tumor-specific glycosylation can create markers that the immune system recognizes. - Better discovery workflows could help researchers generate antibodies against targets that have been difficult to hit with conventional approaches. - The new workflow is aimed at improving therapeutic antibody development for oncology and related diagnostic programs.

What happened: - Creative Biolabs announced an expanded anti-glycopeptide antibody development capability on June 29, 2026, in Shirley, New York. - The company introduced an optimized discovery framework for glycopeptide-targeted programs. - The workflow is built to address weak immunogenicity, cross-reactivity and antigen instability. - Creative Biolabs said the platform is meant to support high-affinity IgG antibody generation against clinically relevant glycopeptide targets.

The details: - The platform combines proprietary glyco-conjugation technologies, advanced adjuvant strategies and high-throughput screening. - Creative Biolabs said the approach is designed to better mimic native glycopeptide conformations found on cell surfaces. - The company’s high-throughput glycopeptide microarray screening platform tests thousands of antibody candidates. - The screening panels include target glycopeptides, structurally related glycans and unglycosylated peptide backbones. - The goal is to identify lead clones with strong specificity earlier and reduce off-target binding risk. - Creative Biolabs offers anti-CD43 glycopeptide antibody development for Tn- and sTn-associated glycopeptide epitopes on CD43. - Creative Biolabs also offers custom glycopeptide target antibody development from antigen synthesis through antibody generation, characterization and preclinical validation. - The company said its counter-screening workflow tests clones against the immunizing glycopeptide, the naked peptide and an irrelevant protein scaffold carrying the same glycan. - Only clones that bind the glycopeptide and not the peptide or irrelevant scaffold are selected. - Creative Biolabs said it has experience targeting MUC4, MUC16, MUC5AC, Podocalyxin, CD43 and CD44. - The company said custom services can target any protein with a known or suspected glycosylation-site biomarker. - Researchers can learn more at the company's glycan-targeting solutions.

Between the lines: - The announcement reflects a broader push to turn tumor-associated glycan biology into usable antibody programs. - The emphasis on counter-screening suggests specificity remains a central risk in glycopeptide antibody discovery. - The company is positioning its platform around both discovery speed and target selectivity, two areas that often determine whether early-stage antibody programs move forward.

What's next: - Creative Biolabs is offering the workflow to researchers working on anti-glycopeptide antibody development. - The company is likely to use the expanded service set to support more client-defined targets and preclinical programs. - Interest may grow around targets tied to tumor-specific glycosylation patterns, especially in oncology research.

The bottom line: - Creative Biolabs is betting that a more structured discovery and screening process can make glycopeptide antibody development more practical for cancer research.